IT1314232B1 - Complexes of paroxetine with cyclodextrin or cyclodextrin derivatives useful for treating depression or Parkinson's disease and other pathologies curable with paroxetine - Google Patents
Complexes of paroxetine with cyclodextrin or cyclodextrin derivatives useful for treating depression or Parkinson's disease and other pathologies curable with paroxetineInfo
- Publication number
- IT1314232B1 IT1314232B1 ITMI992406A IT1314232B1 IT 1314232 B1 IT1314232 B1 IT 1314232B1 IT MI992406 A ITMI992406 A IT MI992406A IT 1314232 B1 IT1314232 B1 IT 1314232B1
- Authority
- IT
- Italy
- Prior art keywords
- cyclodextrin
- paroxetine
- complexes
- pathologies
- parkinson
- Prior art date
Links
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 6
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title abstract 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002296 paroxetine Drugs 0.000 title abstract 3
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- 238000003756 stirring Methods 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 239000002585 base Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000007970 homogeneous dispersion Substances 0.000 abstract 1
- 239000012456 homogeneous solution Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Complexes (I) of paroxetine (P), as free base or as salt, with a cyclodextrin or with a cyclodextrin derivative, are new. Independent claims are also included for the preparation of (I) by: (1) mixing (P), a cyclodextrin or its derivative and water, stirring the mixture to obtain an homogeneous solution or dispersion and continuing stirring until formation of the complex and partially removing water to obtain a solid complex with the desired water content; or (2) slowly adding (P) base in the form of an oily liquid to a cyclodextrin or to its derivative in a mixer for powders or in an ultrasonic mixer and continuing the stirring for 3-24 hours at 25-50 [deg]C. ACTIVITY : Antiparkinsonian; antidepressant. MECHANISM OF ACTION : Inhibitor of neuronal recaptation of serotonin.
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT99MI002406 IT1314232B1 (en) | 1999-11-17 | 1999-11-17 | Complexes of paroxetine with cyclodextrin or cyclodextrin derivatives useful for treating depression or Parkinson's disease and other pathologies curable with paroxetine |
| AT00940418T ATE248165T1 (en) | 1999-07-01 | 2000-06-30 | COMPLEXES OF PAROXETINE WITH CYCLODEXTRIN OR CYCLODEXTRIN DERIVATIVES |
| PCT/EP2000/006121 WO2001002393A1 (en) | 1999-07-01 | 2000-06-30 | Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives |
| DE60004768T DE60004768T2 (en) | 1999-07-01 | 2000-06-30 | COMPLEXES OF PAROXETINE WITH CYCLODEXTRIN OR CYCLODEXTRIN DERIVATIVES |
| DK00940418T DK1109806T3 (en) | 1999-07-01 | 2000-06-30 | Complexes of paroxetine with cyclodextrins or cyclodextrin derivatives |
| US09/763,581 US6984632B1 (en) | 1999-07-01 | 2000-06-30 | Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives |
| ES00940418T ES2206254T3 (en) | 1999-07-01 | 2000-06-30 | PAROXETINE COMPLEXES WITH CYCLODEXTRINES OR DERIVATIVES OF CYCLODEXTRINS. |
| AU55359/00A AU5535900A (en) | 1999-07-01 | 2000-06-30 | Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives |
| KR1020017002289A KR100759159B1 (en) | 1999-07-01 | 2000-06-30 | Complex of paroxetine, with cyclodextrins or cyclodextrin derivatives |
| BR0006838-1A BR0006838A (en) | 1999-07-01 | 2000-06-30 | Paroxetine complexes, with cyclodextrins or cyclodextrin derivatives |
| JP2001507830A JP2003503493A (en) | 1999-07-01 | 2000-06-30 | Complexes of paroxetine with cyclodextrin or cyclodextrin derivatives |
| EP00940418A EP1109806B8 (en) | 1999-07-01 | 2000-06-30 | Complexes of paroxetine, with cyclodextrins or cyclodextrin derivates |
| CA002341984A CA2341984A1 (en) | 1999-07-01 | 2000-06-30 | Complexes of paroxetine, with cyclodextrines or cyclodextrin derivatives |
| PT00940418T PT1109806E (en) | 1999-07-01 | 2000-06-30 | PAROXETINE COMPLEXES WITH CYCLLODEXTRINS OR CYCLODEXTRINES DERIVATIVES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT99MI002406 IT1314232B1 (en) | 1999-11-17 | 1999-11-17 | Complexes of paroxetine with cyclodextrin or cyclodextrin derivatives useful for treating depression or Parkinson's disease and other pathologies curable with paroxetine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITMI992406A0 ITMI992406A0 (en) | 1999-11-17 |
| ITMI992406A1 ITMI992406A1 (en) | 2001-05-17 |
| IT1314232B1 true IT1314232B1 (en) | 2002-12-06 |
Family
ID=11383976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT99MI002406 IT1314232B1 (en) | 1999-07-01 | 1999-11-17 | Complexes of paroxetine with cyclodextrin or cyclodextrin derivatives useful for treating depression or Parkinson's disease and other pathologies curable with paroxetine |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT1314232B1 (en) |
-
1999
- 1999-11-17 IT IT99MI002406 patent/IT1314232B1/en active
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI992406A1 (en) | 2001-05-17 |
| ITMI992406A0 (en) | 1999-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0303511A2 (en) | Conjugates of hydroxyalkyl starch, process for their preparation and their use | |
| TNSN00202A1 (en) | NOVEL N - [(PURINE - 2- YL) METHYL] -SULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | |
| CA2289202A1 (en) | Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent | |
| BR0116113A (en) | Spiro [isobenzofuran-1,4'-piperidin] -3-ones and 3h-spiroisoben-zofuran-1,4'-piperidines | |
| MY126973A (en) | Derivatives of 4-aminopiperidine and their use as a medicament | |
| TNSN98176A1 (en) | TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING RESORCINOL DERIVATIVES | |
| CA2332007A1 (en) | Adenosine a3 receptor modulators | |
| TNSN00203A1 (en) | NEW PURINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | |
| TNSN01082A1 (en) | NOVEL THIOPHENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | |
| PT1254146E (en) | CLARITROMYCINE POLYMER PREPARATION PROCESSES AND NEW POLYMORPH IV | |
| BR9912627A (en) | Composition in stable liquid suspension, and processes for preparing and using it and for treating weight and cholesterol | |
| WO2005007648A3 (en) | Biaryl piperazinyl-pyridine analogues | |
| TNSN99177A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDO [1, 2-a] PYRAZINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | |
| EP1612208A3 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
| AP2001002377A0 (en) | Substituted phenoxyacetic acids. | |
| BR0314754A (en) | Therapeutic or prophylactic agent for urinary frequency or urinary incontinence or a pharmaceutically acceptable acid addition salt thereof, method for urinary frequency therapy or prophylaxis, urinary urgency or urinary incontinence, use of a morphine derivative having a nitrogen-containing heterocyclic group or a pharmaceutically acceptable acid addition salt thereof, morphine derivative or a pharmaceutically acceptable acid addition salt thereof, pharmaceutical, and pharmaceutical composition | |
| Boger et al. | Second definitive test of proposed models for the origin of the CC-1065 and duocarmycin DNA alkylation selectivity | |
| WO2000002551A3 (en) | Methods and compounds for treating depression | |
| IT1314232B1 (en) | Complexes of paroxetine with cyclodextrin or cyclodextrin derivatives useful for treating depression or Parkinson's disease and other pathologies curable with paroxetine | |
| WO2000078776A3 (en) | Thiophene a2a receptor agonists | |
| MY152878A (en) | Novel cosmetic cream composition comprising c12-c20 fatty acid | |
| CA2389476A1 (en) | Treatment of dyskinesia with a h3-histamine receptor agonist | |
| BRPI0412908A (en) | compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods for treating anxiety, depression, a sleep disorder, attention deficit disorder or alzheimer's dementia, to enhance a therapeutic effect of a cns agent, to improve memory in a patient, to alter gabaa receptor signal transduction activity, and to determine the presence or absence of gabaa receptor in a sample, packaged pharmaceutical preparation, and use of a compound or salt | |
| AU2003276514A1 (en) | 4-imidazol-1-ylmethyl-pyrimidine derivatives_as ligands for gabaa receptors | |
| TW200621770A (en) | A complex comprising mequitazine, a cyclodextrin, and an interaction agent |